Loading...
•
Dec 31, 2021
Orthofix Q4 2021 Earnings Report
Orthofix's financial performance was reported for Q4 2021, showing increased net sales and strategic advancements.
Key Takeaways
Orthofix reported a 6% increase in net sales for the fourth quarter of 2021, driven by double-digit growth in Global Spinal Implants and Orthopedics. Despite headwinds, the company delivered double-digit revenue growth and advanced strategic initiatives. The company anticipates accelerating top line growth in 2022 and beyond.
Net sales for the fourth quarter increased by 6% year-over-year to $125.1 million.
Double-digit net sales growth was achieved in both Global Spinal Implants and Orthopedics compared to the prior year period.
EPS was $(1.65) and adjusted EPS was $0.27 for the fourth quarter.
The company entered into a partnership and investment with nView medical.
Revenue by Segment
Forward Guidance
The Company expects net sales between $475.0 million and $490.0 million, adjusted EBITDA between $56.0 million and $61.0 million, and adjusted EPS between $0.58 and $0.73 for the year ended December 31, 2022.
Positive Outlook
- Net sales are expected to increase by 2% to 5% on a reported basis.
- Net sales are expected to increase by 3% to 6% on a constant currency basis.
Challenges Ahead
- Adjusted EBITDA is expected to decrease by 9% to 0%.
- Adjusted EPS is expected to decrease by 33% to 15%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...